{"id":651478,"date":"2023-05-15T17:38:01","date_gmt":"2023-05-15T17:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=651478"},"modified":"2023-05-15T17:38:01","modified_gmt":"2023-05-15T17:38:01","slug":"neuroendocrine-tumors-market-size-and-share-market-research-report-2032-companies-pfizer-epicentrx-amgen","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/neuroendocrine-tumors-market-size-and-share-market-research-report-2032-companies-pfizer-epicentrx-amgen_651478.html","title":{"rendered":"Neuroendocrine Tumors Market Size and Share, Market Research Report 2032 | Companies – Pfizer, EpicentRx, Amgen"},"content":{"rendered":"
\n
\"Neuroendocrine<\/a><\/div>\n
\n
Neuroendocrine Tumors Market<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Neuroendocrine Tumors – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Neuroendocrine Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight launched a new report on Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast 2032<\/a>.<\/p>\n

DelveInsight’s “Neuroendocrine Tumors Market Report 2032<\/a>“ delivers an in-depth understanding of the Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Neuroendocrine Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts but can occur in many areas of the body.<\/p>\n

Request for free sample pages of the report: https:\/\/www.delveinsight.com\/sample-request\/neuroendocrine-tumors-market<\/a><\/p>\n

Neuroendocrine tumors are cancers that begin in specialized cells called neuroendocrine cells. Neuroendocrine cells have traits similar to those of nerve cells and hormone-producing cells. Neuroendocrine tumors are rare and can occur anywhere in the body.<\/p>\n

The signs and symptoms associated with the disease depend on the place of origin of the tumor within the human body. At times the disease may not cause any signs or symptoms if they are slow-growing and do not secrete much of a certain hormone.<\/p>\n

The total prevalence of NETS was estimated at approximately 453,191 in 2019, for 7MM.<\/p>\n

Key pharma players involved:<\/p>\n